
    
      The study will follow the real-life management of patients in clinical practice. Visits will
      take place according to the study site's clinical practice. Cabozantinib is to be
      administered as directed by the investigator according to the study site's usual clinical
      practice and the Cabometyxâ„¢ Summary of Product Characteristics (SmPC).
    
  